Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Non-Current Assets: 2022-2024

Historic Other Non-Current Assets for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $121,000.

  • Day One Biopharmaceuticals' Other Non-Current Assets rose 170.94% to $317,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $317,000, marking a year-over-year increase of 170.94%. This contributed to the annual value of $121,000 for FY2024, which is 43.46% down from last year.
  • Day One Biopharmaceuticals' Other Non-Current Assets amounted to $121,000 in FY2024, which was down 43.46% from $214,000 recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Other Non-Current Assets peaked at $469,000 during FY2022, and registered a low of $121,000 during FY2024.
  • Its 3-year average for Other Non-Current Assets is $268,000, with a median of $214,000 in 2023.
  • Data for Day One Biopharmaceuticals' Other Non-Current Assets shows a maximum YoY slumped of 54.37% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Other Non-Current Assets stood at $469,000 in 2022, then tumbled by 54.37% to $214,000 in 2023, then tumbled by 43.46% to $121,000 in 2024.